Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Green tea polyphenol formulations developed by Topix Pharmaceuticals are topical cosmeceutical products designed to treat sensitive skin and reduce oxidative stress. These formulations contain high concentrations of purified green tea polyphenols (GTP), particularly epigallocatechin-3-gallate (EGCG), which is the most active component. The technology focuses on stabilizing these polyphenols to maintain their potency in topical vehicles like creams and serums. Mechanistically, GTPs act as powerful antioxidants that neutralize reactive oxygen species (ROS) generated by UV radiation and environmental pollutants, while also providing anti-inflammatory effects by modulating signaling pathways such as NF-kappaB. These products are primarily indicated for soothing redness, managing rosacea-prone skin, and providing anti-aging benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on green tea polyphenol formulations.